For most biotechnology companies, Latin America is not a strategic priority. That is usually understandable. The United States remains the world's largest biopharmaceutical market. Western Europe combines world-class academic research, mature clinical research infrastructure, established regulatory systems, and large commercial markets. Central and Eastern Europe has long been valued for experienced investigators and efficient patient recruitment. China, Japan, and other Asia
